HUP0400781A2 - Eljárás (R)- vagy (S)-lansoprazol kristályosítására, az előállított kristályok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
Eljárás (R)- vagy (S)-lansoprazol kristályosítására, az előállított kristályok, azokat tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0400781A2 HUP0400781A2 HU0400781A HUP0400781A HUP0400781A2 HU P0400781 A2 HUP0400781 A2 HU P0400781A2 HU 0400781 A HU0400781 A HU 0400781A HU P0400781 A HUP0400781 A HU P0400781A HU P0400781 A2 HUP0400781 A2 HU P0400781A2
- Authority
- HU
- Hungary
- Prior art keywords
- lansoprazole
- methyl
- crystalls
- crystallization
- prepared
- Prior art date
Links
- MJIHNNLFOKEZEW-VWLOTQADSA-N 2-[(s)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-VWLOTQADSA-N 0.000 title abstract 5
- MJIHNNLFOKEZEW-RUZDIDTESA-N dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 238000002425 crystallisation Methods 0.000 title 1
- 230000008025 crystallization Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229960003568 dexlansoprazole Drugs 0.000 abstract 3
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány tárgya eljárás kristályos (R)-lansoprazol[(R)-2-({[3-metil-4-(2,2,2-trifluoretoxi)-2-piridinil]metil}szulfinil)-1H-benzimidazol] vagy (S)-lansoprazol[(S)-2-({[3-metil-4-(2,2,2-trifluoretoxi)-2-piridinil]metil}szulfinil)-1H-benzimidazol]előállítására, amelynek megfelelően a körülbelül 0,1 g/ml éskörülbelül 0,5 g/ml közötti koncentrációjú, 1-4 szénatomosalkilacetátos (R)-lansoprazol vagy (S)-lansoprazol-oldatot körülbelül0 °C és 35 °C közötti hőmérsékleten kristályosítják. A találmány még afenti eljárással előállított kristályokra, azokat tartalmazógyógyszerkészítményekre és azok különböző fekélyes betegségekkezelésére vagy megelőzésére való alkalmazására vonatkozik. Atalálmány szerinti eljárással hatékonyan lehet előállítani ipariméretekben kimagasló tárolási stabilitással rendelkező kristályos (R)-lansoprazolt vagy (S)-lansoprazolt. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000367757 | 2000-12-01 | ||
PCT/JP2001/010462 WO2002044167A1 (en) | 2000-12-01 | 2001-11-30 | Process for the crystallization of (r)- or (s)-lansoprazole |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0400781A2 true HUP0400781A2 (hu) | 2004-07-28 |
HUP0400781A3 HUP0400781A3 (en) | 2010-03-29 |
HU229356B1 HU229356B1 (en) | 2013-11-28 |
Family
ID=18838123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400781A HU229356B1 (en) | 2000-12-01 | 2001-11-30 | Process for the crystallization of (r)- or (s)-lansoprazole |
Country Status (17)
Country | Link |
---|---|
US (2) | US7285668B2 (hu) |
EP (2) | EP2345650A1 (hu) |
KR (3) | KR20100002278A (hu) |
CN (1) | CN1254473C (hu) |
AT (1) | ATE511508T1 (hu) |
AU (1) | AU2002218506A1 (hu) |
CA (1) | CA2436825C (hu) |
CY (1) | CY1112347T1 (hu) |
DK (1) | DK1337525T3 (hu) |
ES (1) | ES2367419T3 (hu) |
HK (1) | HK1054380B (hu) |
HU (1) | HU229356B1 (hu) |
NO (1) | NO326019B1 (hu) |
PL (3) | PL214684B1 (hu) |
PT (1) | PT1337525E (hu) |
TW (1) | TWI290922B (hu) |
WO (1) | WO2002044167A1 (hu) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020027315A1 (en) * | 2000-03-10 | 2002-03-07 | Parker Gerard E. | Low-firing temperature method for producing Al2O3 bodies having enhanced chemical resistance |
DE60131649T2 (de) | 2000-05-15 | 2008-10-30 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung eines kristalls |
IL164153A0 (en) * | 2002-03-27 | 2005-12-18 | Teval Pharmaceutical Ind Ltd | Lansoprazole polymorphs and processes for preparation thereof |
CA2771725C (en) * | 2002-10-16 | 2015-08-18 | Takeda Pharmaceutical Company Limited | Solid preparation comprising a non-toxic base and a proton pump inhibitor |
AU2004207720A1 (en) * | 2003-01-31 | 2004-08-12 | Teijin Pharma Limited | Crystal of (23S)-1alpha-hydroxy-27-nor-25-methylenevitamin D3-26,23-lactone and process for producing the same |
US20050220870A1 (en) * | 2003-02-20 | 2005-10-06 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
US8993599B2 (en) * | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
WO2005007117A2 (en) * | 2003-07-18 | 2005-01-27 | Santarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
TWI398273B (zh) * | 2003-07-18 | 2013-06-11 | Santarus Inc | 用於抑制酸分泌之醫藥調配物及其製備及使用之方法 |
US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
EP1718303A4 (en) * | 2004-02-10 | 2010-09-01 | Santarus Inc | COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG |
US20050239845A1 (en) * | 2004-04-16 | 2005-10-27 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and prokinetic agent |
US8906940B2 (en) * | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
AU2005264864B2 (en) | 2004-06-16 | 2011-08-11 | Takeda Pharmaceutical Company Limited | Multiple PPI dosage form |
EP1681056A1 (en) * | 2005-01-14 | 2006-07-19 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process for preparing lansoprazole |
CA2624179A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
EP1967183A4 (en) | 2005-12-28 | 2011-02-23 | Takeda Pharmaceutical | SOLID PREPARATION WITH CONTROLLED RELEASE |
KR100758600B1 (ko) * | 2006-01-05 | 2007-09-13 | 주식회사 대웅제약 | 란소프라졸 결정형 a의 제조방법 |
US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
US9486446B2 (en) | 2006-12-28 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Orally disintegrating solid preparation |
WO2008087665A2 (en) * | 2007-01-18 | 2008-07-24 | Matrix Laboratories Ltd | Process for preparation of lansoprazole |
KR101303813B1 (ko) | 2007-04-16 | 2013-09-04 | 에스케이케미칼주식회사 | 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법 |
RU2010119041A (ru) * | 2007-10-12 | 2011-11-20 | Такеда Фармасьютикалз Норт Америка, Инк. (Us) | Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи |
NZ593629A (en) * | 2007-12-18 | 2012-11-30 | Watson Pharma Private Ltd | Stable amorphous R-lansoprazole prepared by optically resolving racemic lansoprazole |
EA017064B1 (ru) * | 2008-03-10 | 2012-09-28 | Такеда Фармасьютикал Компани Лимитед | Кристаллическое производное бензимидазола |
NZ589150A (en) * | 2008-05-14 | 2012-03-30 | Watson Pharma Private Ltd | Stable r (+) -lansoprazole amine salt and a process for preparing the same |
WO2010039885A2 (en) * | 2008-09-30 | 2010-04-08 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of dexlansoprazole |
KR101321055B1 (ko) * | 2008-11-14 | 2013-10-23 | 한미사이언스 주식회사 | 덱스란소프라졸의 신규 결정형 및 이를 포함하는 약학 조성물 |
IT1391776B1 (it) * | 2008-11-18 | 2012-01-27 | Dipharma Francis Srl | Procedimento per la preparazione di dexlansoprazolo |
WO2010095144A2 (en) * | 2009-02-04 | 2010-08-26 | Msn Laboratories Limited | Process for the preparation of proton pump inhibitors |
IT1392813B1 (it) * | 2009-02-06 | 2012-03-23 | Dipharma Francis Srl | Forme cristalline di dexlansoprazolo |
US20110009637A1 (en) * | 2009-02-10 | 2011-01-13 | Dario Braga | Crystals of Dexlansoprazole |
WO2011004387A2 (en) | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | Process for the preparation of dexlansoprazole polymorphic forms |
IT1395118B1 (it) * | 2009-07-29 | 2012-09-05 | Dipharma Francis Srl | Procedimento per la preparazione di dexlansoprazolo cristallino |
US20130197232A1 (en) | 2010-01-29 | 2013-08-01 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline forms of dexlansoprazole |
CA2795110C (en) | 2010-03-31 | 2015-06-09 | Ranbaxy Laboratories Limited | Process for the preparation of dexlansoprazole |
WO2011121546A1 (en) | 2010-03-31 | 2011-10-06 | Ranbaxy Laboratories Limited | Salts of dexlansoprazole and their preparation |
US20130216617A1 (en) | 2010-06-29 | 2013-08-22 | Cadila Healthcare Limited | Pharmaceutical compositions of (r)-lansoprazole |
PE20140005A1 (es) | 2010-12-03 | 2014-01-23 | Takeda Pharmaceutical | Tableta oralmente desintegradora |
EA028217B1 (ru) | 2010-12-27 | 2017-10-31 | Такеда Фармасьютикал Компани Лимитед | Разрушающаяся во рту таблетка (варианты) |
WO2012104805A1 (en) | 2011-02-01 | 2012-08-09 | Ranbaxy Laboratories Limited | Process for the preparation of dexlansoprazole |
AU2012274967A1 (en) | 2011-06-21 | 2014-01-23 | Sun Pharmaceutical Industries Limited | Process for the preparation of dexlansoprazole |
CN102234265B (zh) * | 2011-08-08 | 2013-11-20 | 天津市汉康医药生物技术有限公司 | 兰索拉唑化合物 |
ES2561098T3 (es) | 2011-11-30 | 2016-02-24 | Takeda Pharmaceutical Company Limited | Comprimido recubierto en seco |
IN2014CN04228A (hu) | 2011-12-29 | 2015-07-17 | Intel Corp | |
WO2013140120A1 (en) | 2012-03-22 | 2013-09-26 | Cipla Limited | Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole |
WO2013179194A1 (en) | 2012-05-31 | 2013-12-05 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline dexlansoprazole |
TW201532635A (zh) | 2013-05-21 | 2015-09-01 | Takeda Pharmaceutical | 口腔內崩解錠 |
CN103254174B (zh) * | 2013-06-05 | 2014-06-11 | 湖北济生医药有限公司 | 一种兰索拉唑化合物及其药物组合物 |
CN105339399B (zh) | 2013-06-20 | 2018-01-02 | 日本聚丙烯株式会社 | 丙烯系嵌段共聚物 |
CN104958276A (zh) * | 2015-07-30 | 2015-10-07 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗胃溃疡的药物兰索拉唑组合物胶囊 |
CN104997739A (zh) * | 2015-08-31 | 2015-10-28 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗消化系统疾病的药物兰索拉唑组合物冻干粉针剂 |
CN105399728B (zh) * | 2015-12-20 | 2017-11-28 | 寿光富康制药有限公司 | 一种适用于工业化生产的右兰索拉唑的处理方法 |
CN106279107A (zh) * | 2016-08-10 | 2017-01-04 | 成都尚药科技有限公司 | 一种右旋兰索拉唑晶型的制备方法 |
CN106749182A (zh) * | 2016-11-08 | 2017-05-31 | 山东裕欣药业有限公司 | 一种右旋兰索拉唑晶型化合物及其制备方法 |
IT201700050223A1 (it) | 2017-05-09 | 2018-11-09 | Dipharma Francis Srl | Procedimento per la preparazione di dexlansoprazolo cristallino |
WO2024075017A1 (en) | 2022-10-04 | 2024-04-11 | Zabirnyk Arsenii | Inhibition of aortic valve calcification |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6150978A (ja) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
DK171989B1 (da) | 1987-08-04 | 1997-09-08 | Takeda Chemical Industries Ltd | Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler |
SE504459C2 (sv) | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
HRP960232A2 (en) | 1995-07-03 | 1998-02-28 | Astra Ab | A process for the optical purification of compounds |
JPH1085502A (ja) * | 1996-09-19 | 1998-04-07 | Konica Corp | 晶析方法 |
JP3828648B2 (ja) | 1996-11-14 | 2006-10-04 | 武田薬品工業株式会社 | 2−(2−ピリジルメチルスルフィニル)ベンズイミダゾール系化合物の結晶およびその製造法 |
TW385306B (en) | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
CN1238694A (zh) * | 1996-11-22 | 1999-12-15 | 普罗克特和甘保尔公司 | 治疗肠胃病用的含铋和nsaid的组合物 |
JP2002501896A (ja) * | 1998-01-30 | 2002-01-22 | セプラコール, インク. | S−ランソプラゾール組成物及び方法 |
JP3283252B2 (ja) * | 1999-06-17 | 2002-05-20 | 武田薬品工業株式会社 | ベンズイミダゾール化合物の結晶 |
JP4536905B2 (ja) * | 1999-06-17 | 2010-09-01 | 武田薬品工業株式会社 | ベンズイミダゾール化合物の結晶 |
TWI289557B (en) * | 1999-06-17 | 2007-11-11 | Takeda Chemical Industries Ltd | A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
PT1191025E (pt) * | 1999-06-30 | 2005-09-30 | Takeda Pharmaceutical | Cristais de lansoprazol |
JP2001039975A (ja) * | 1999-07-26 | 2001-02-13 | Eisai Co Ltd | スルホキシド誘導体の結晶およびその製造法 |
AU6727700A (en) | 1999-08-25 | 2001-03-19 | Takeda Chemical Industries Ltd. | Process for the preparation of optically active sulfoxide derivatives |
DE60124692T2 (de) | 2000-04-28 | 2007-09-13 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung von optisch-aktiven sulfoxid-derivaten |
DE60131649T2 (de) | 2000-05-15 | 2008-10-30 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung eines kristalls |
CN1117747C (zh) * | 2000-06-19 | 2003-08-13 | 中国科学院成都有机化学研究所 | 光学纯兰索拉唑的制备方法 |
-
2001
- 2001-11-30 KR KR1020097023619A patent/KR20100002278A/ko not_active Application Discontinuation
- 2001-11-30 EP EP10177469A patent/EP2345650A1/en not_active Ceased
- 2001-11-30 CN CNB018198163A patent/CN1254473C/zh not_active Expired - Lifetime
- 2001-11-30 AU AU2002218506A patent/AU2002218506A1/en not_active Abandoned
- 2001-11-30 PL PL362801A patent/PL214684B1/pl unknown
- 2001-11-30 TW TW090129629A patent/TWI290922B/zh not_active IP Right Cessation
- 2001-11-30 KR KR1020037007334A patent/KR100887912B1/ko active IP Right Grant
- 2001-11-30 PL PL409463A patent/PL409463A1/pl unknown
- 2001-11-30 US US10/432,798 patent/US7285668B2/en not_active Expired - Lifetime
- 2001-11-30 PL PL399787A patent/PL399787A1/pl unknown
- 2001-11-30 KR KR1020087028441A patent/KR100939948B1/ko active IP Right Grant
- 2001-11-30 EP EP01998545A patent/EP1337525B8/en not_active Expired - Lifetime
- 2001-11-30 DK DK01998545.6T patent/DK1337525T3/da active
- 2001-11-30 AT AT01998545T patent/ATE511508T1/de active
- 2001-11-30 WO PCT/JP2001/010462 patent/WO2002044167A1/en not_active Application Discontinuation
- 2001-11-30 ES ES01998545T patent/ES2367419T3/es not_active Expired - Lifetime
- 2001-11-30 CA CA2436825A patent/CA2436825C/en not_active Expired - Lifetime
- 2001-11-30 HU HU0400781A patent/HU229356B1/hu unknown
- 2001-11-30 PT PT01998545T patent/PT1337525E/pt unknown
-
2003
- 2003-05-28 NO NO20032437A patent/NO326019B1/no not_active IP Right Cessation
- 2003-09-13 HK HK03106568.6A patent/HK1054380B/zh not_active IP Right Cessation
-
2007
- 2007-09-07 US US11/899,918 patent/US20080306118A1/en not_active Abandoned
-
2011
- 2011-08-24 CY CY20111100809T patent/CY1112347T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0400781A2 (hu) | Eljárás (R)- vagy (S)-lansoprazol kristályosítására, az előállított kristályok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
NO20044731L (no) | Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere | |
HUP0102472A2 (hu) | Nitrogén-oxid szintáz inhibitorként alkalmazható amidinoszármazékok, eljárás az előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
HUP0102084A2 (hu) | Kinolinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0103063A2 (hu) | Új 2H-piridazin-származékok, alkalmazásuk, ilyen hatóanyagot tartalmazó gyógyászati készítmények, és eljárás a hatóanyag előállítására | |
HUP0203438A2 (hu) | Foszfodiészteráz gátló hatású 5-(2-helyettesített-5-heterociklilszulfonilpirid-3-il)-dihidropirazolo[4,3-d]-pirimidin-7-on-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
IS2734B (is) | Pýrasólafleiður og notkun þar á, ásamt lyfjasamsetningum | |
NO20055421L (no) | Kinolinderivater som fosfodiestrase-inhibitorer | |
NO20093464L (no) | Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika | |
NO20025601L (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
HUP0100865A2 (hu) | Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
NO20050573L (no) | 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler | |
HUP0400368A2 (hu) | Oxitocin agonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk szexuális zavarok kezelésére | |
MD1688F2 (en) | Benzothiophene, benzofuran and indolethiazepinons, oxazepinons and diazepinons, pharmaceutical composition, method of inhibiting the leucocytes adherence to the endothelial cells for inflammatory diseases treatment and method of treatment of the mammals affected by the HIV infection | |
ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
DK1664123T4 (da) | Storskalafremstilling af alfa-1-proteinaseinhibitor og anvendelse deraf | |
AR035465A1 (es) | Compuestos de imidazopiridina, procesos para su preparacion,formulacion farmaceutica, usos de estos compuestos para la fabricacion de medicamentos e intermediarios | |
SE0302756D0 (sv) | Novel Compounds | |
SE9803773D0 (sv) | Compounds | |
NO912414L (no) | Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling. | |
GB0223232D0 (en) | Chemical compounds | |
HUP0400389A2 (hu) | CCR5 antagonistákként alkalmazható aril-oxim piperazinok és ezeket tartalmazó gyógyszerkészítmények | |
HUP0301594A2 (hu) | E-metanikotin diacilborkősav sóját tartalmazó gyógyászati készítmények és alkalmazásuk a központi idegrendszer rendellenességeinek kezelésére | |
PT1218401E (pt) | 4-benzilaminoquinolinas conjugadas com acido biliar e seus heterociclicos metodos de sua producao medicamentos contendo estes compostos e sua aplicacao | |
HUP0303676A2 (hu) | Helyettesített 4-fenil-1-(1-fenil-ciklohexil)-1,2,3,6-tetrahidropiridinek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |